AG˹ٷ

STOCK TITAN

[Form 4] Sight Sciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Sight Sciences, Inc. (SGHT) � Form 4 insider transaction

Chief Technology Officer & Director David Badawi disclosed the sale of 5,679 common shares on 03 July 2025 at an average price of $4.174 per share. The disposition was executed to satisfy statutory tax-withholding obligations generated by the vesting of restricted stock units, as noted in the filing’s footnote.

Following the sale, Badawi’s direct beneficial ownership stands at 1,831,025 shares. No derivative securities were reported, and there were no purchases.

The Form 4 indicates an automatic, non-discretionary sale (code “S�) under Rule 16a to cover taxes, which generally carries less negative signaling than voluntary open-market sales. The transaction represents approximately 0.3 % of Badawi’s post-transaction holdings and an immaterial percentage of SGHT’s total shares outstanding.

Sight Sciences, Inc. (SGHT) � Transazione interna Form 4

Il Chief Technology Officer e Direttore David Badawi ha comunicato la vendita di 5.679 azioni ordinarie il 03 luglio 2025 ad un prezzo medio di $4,174 per azione. La cessione è stata effettuata per adempiere agli obblighi fiscali derivanti dal vincolo delle unità azionarie ristrette, come indicato nella nota a piè di pagina del documento.

Dopo la vendita, la proprietà diretta di Badawi ammonta a 1.831.025 azioni. Non sono stati segnalati titoli derivati né acquisti.

Il Form 4 indica una vendita automatica e non discrezionale (codice “S�) ai sensi della Regola 16a per coprire le imposte, generalmente meno negativa rispetto alle vendite volontarie sul mercato aperto. L’operazione rappresenta circa lo 0,3% delle partecipazioni di Badawi dopo la transazione e una percentuale irrilevante del totale delle azioni SGHT in circolazione.

Sight Sciences, Inc. (SGHT) � Transacción interna Formulario 4

El Director de Tecnología y Director David Badawi informó la venta de 5,679 acciones ordinarias el 3 de julio de 2025 a un precio promedio de $4.174 por acción. La disposición se realizó para cumplir con las obligaciones fiscales derivadas del otorgamiento de unidades de acciones restringidas, como se indica en la nota al pie del documento.

Tras la venta, la propiedad directa de Badawi es de 1,831,025 acciones. No se reportaron valores derivados ni compras.

El Formulario 4 señala una venta automática y no discrecional (código “S�) bajo la Regla 16a para cubrir impuestos, lo que generalmente genera menos señales negativas que las ventas voluntarias en el mercado abierto. La transacción representa aproximadamente el 0,3 % de las acciones que Badawi posee tras la operación y un porcentaje insignificante del total de acciones en circulación de SGHT.

Sight Sciences, Inc. (SGHT) � Form 4 내부� 거래 보고

최고기술책임� � 이사� David Badawi가 2025� 7� 3일에 5,679� 보통� 매도� 공시했으�, 주당 평균 가격은 $4.174였습니�. � 처분은 제한 주식 단위� 권리 확정� 따른 법정 세금 원천징수 의무� 충족하기 위해 이루어졌다고 공시 각주� 명시되어 있습니다.

매도 � Badawi� 직접 소유 주식 수는 1,831,025�입니�. 파생 증권은 보고되지 않았으며 매수� 없었습니�.

Form 4� 세금� 충당하기 위한 � 16a� 따른 자동 비재량적 매도(코드 “S�)임을 나타내며, 이는 일반적으� 자발� 공개시장 매도보다 부정적 신호가 적습니다. 이번 거래� Badawi� 거래 � 보유 주식� � 0.3%� 해당하며 SGHT � 발행 주식� 미미� 비율입니�.

Sight Sciences, Inc. (SGHT) � Transaction d’initié Formulaire 4

Le Directeur Technique et Administrateur David Badawi a déclaré la vente de 5 679 actions ordinaires le 3 juillet 2025 à un prix moyen de 4,174 $ par action. La cession a été réalisée pour satisfaire aux obligations fiscales légales générées par l’acquisition des unités d’actions restreintes, comme indiqué en note de bas de page du dossier.

Après la vente, la détention directe de Badawi s’élève à 1 831 025 actions. Aucun titre dérivé n’a été déclaré et aucun achat n’a eu lieu.

Le Formulaire 4 indique une vente automatique et non discrétionnaire (code « S ») selon la règle 16a pour couvrir les taxes, ce qui est généralement perçu comme moins négatif que des ventes volontaires sur le marché ouvert. La transaction représente environ 0,3 % des avoirs de Badawi après la transaction et une part négligeable du total des actions en circulation de SGHT.

Sight Sciences, Inc. (SGHT) � Form 4 Insider-Transaktion

Der Chief Technology Officer und Direktor David Badawi meldete den Verkauf von 5.679 Stammaktien am 3. Juli 2025 zu einem durchschnittlichen Preis von $4,174 pro Aktie. Die Veräußerung erfolgte zur Erfüllung gesetzlicher Steuerabzugsverpflichtungen, die durch die Vesting-Bedingungen von Restricted Stock Units entstanden sind, wie in der Fußnote der Meldung vermerkt.

Nach dem Verkauf hält Badawi direkt 1.831.025 Aktien. Es wurden keine Derivate gemeldet und keine Käufe getätigt.

Das Formular 4 weist auf einen automatischen, nicht-diskretionären Verkauf (Code „S�) gemäß Regel 16a zur Steuerabdeckung hin, der in der Regel weniger negative Signale als freiwillige Verkäufe am offenen Markt aussendet. Die Transaktion entspricht etwa 0,3 % von Badawis Beständen nach der Transaktion und einem unbedeutenden Anteil an den insgesamt ausstehenden SGHT-Aktien.

Positive
  • Insider retains a large stake: 1,831,025 shares post-sale, suggesting long-term commitment.
Negative
  • Insider sale, even if automatic, can be perceived negatively by some investors.

Insights

TL;DR: Small tax-withholding sale; minimal signalling impact.

The 5,679-share sale (~$24k) is routine for RSU tax coverage. Badawi retains 1.83 million shares, indicating continued alignment with shareholders. Given the modest size relative to his stake and SGHT’s float, the filing is not financially material and unlikely to influence valuation or trading sentiment.

Sight Sciences, Inc. (SGHT) � Transazione interna Form 4

Il Chief Technology Officer e Direttore David Badawi ha comunicato la vendita di 5.679 azioni ordinarie il 03 luglio 2025 ad un prezzo medio di $4,174 per azione. La cessione è stata effettuata per adempiere agli obblighi fiscali derivanti dal vincolo delle unità azionarie ristrette, come indicato nella nota a piè di pagina del documento.

Dopo la vendita, la proprietà diretta di Badawi ammonta a 1.831.025 azioni. Non sono stati segnalati titoli derivati né acquisti.

Il Form 4 indica una vendita automatica e non discrezionale (codice “S�) ai sensi della Regola 16a per coprire le imposte, generalmente meno negativa rispetto alle vendite volontarie sul mercato aperto. L’operazione rappresenta circa lo 0,3% delle partecipazioni di Badawi dopo la transazione e una percentuale irrilevante del totale delle azioni SGHT in circolazione.

Sight Sciences, Inc. (SGHT) � Transacción interna Formulario 4

El Director de Tecnología y Director David Badawi informó la venta de 5,679 acciones ordinarias el 3 de julio de 2025 a un precio promedio de $4.174 por acción. La disposición se realizó para cumplir con las obligaciones fiscales derivadas del otorgamiento de unidades de acciones restringidas, como se indica en la nota al pie del documento.

Tras la venta, la propiedad directa de Badawi es de 1,831,025 acciones. No se reportaron valores derivados ni compras.

El Formulario 4 señala una venta automática y no discrecional (código “S�) bajo la Regla 16a para cubrir impuestos, lo que generalmente genera menos señales negativas que las ventas voluntarias en el mercado abierto. La transacción representa aproximadamente el 0,3 % de las acciones que Badawi posee tras la operación y un porcentaje insignificante del total de acciones en circulación de SGHT.

Sight Sciences, Inc. (SGHT) � Form 4 내부� 거래 보고

최고기술책임� � 이사� David Badawi가 2025� 7� 3일에 5,679� 보통� 매도� 공시했으�, 주당 평균 가격은 $4.174였습니�. � 처분은 제한 주식 단위� 권리 확정� 따른 법정 세금 원천징수 의무� 충족하기 위해 이루어졌다고 공시 각주� 명시되어 있습니다.

매도 � Badawi� 직접 소유 주식 수는 1,831,025�입니�. 파생 증권은 보고되지 않았으며 매수� 없었습니�.

Form 4� 세금� 충당하기 위한 � 16a� 따른 자동 비재량적 매도(코드 “S�)임을 나타내며, 이는 일반적으� 자발� 공개시장 매도보다 부정적 신호가 적습니다. 이번 거래� Badawi� 거래 � 보유 주식� � 0.3%� 해당하며 SGHT � 발행 주식� 미미� 비율입니�.

Sight Sciences, Inc. (SGHT) � Transaction d’initié Formulaire 4

Le Directeur Technique et Administrateur David Badawi a déclaré la vente de 5 679 actions ordinaires le 3 juillet 2025 à un prix moyen de 4,174 $ par action. La cession a été réalisée pour satisfaire aux obligations fiscales légales générées par l’acquisition des unités d’actions restreintes, comme indiqué en note de bas de page du dossier.

Après la vente, la détention directe de Badawi s’élève à 1 831 025 actions. Aucun titre dérivé n’a été déclaré et aucun achat n’a eu lieu.

Le Formulaire 4 indique une vente automatique et non discrétionnaire (code « S ») selon la règle 16a pour couvrir les taxes, ce qui est généralement perçu comme moins négatif que des ventes volontaires sur le marché ouvert. La transaction représente environ 0,3 % des avoirs de Badawi après la transaction et une part négligeable du total des actions en circulation de SGHT.

Sight Sciences, Inc. (SGHT) � Form 4 Insider-Transaktion

Der Chief Technology Officer und Direktor David Badawi meldete den Verkauf von 5.679 Stammaktien am 3. Juli 2025 zu einem durchschnittlichen Preis von $4,174 pro Aktie. Die Veräußerung erfolgte zur Erfüllung gesetzlicher Steuerabzugsverpflichtungen, die durch die Vesting-Bedingungen von Restricted Stock Units entstanden sind, wie in der Fußnote der Meldung vermerkt.

Nach dem Verkauf hält Badawi direkt 1.831.025 Aktien. Es wurden keine Derivate gemeldet und keine Käufe getätigt.

Das Formular 4 weist auf einen automatischen, nicht-diskretionären Verkauf (Code „S�) gemäß Regel 16a zur Steuerabdeckung hin, der in der Regel weniger negative Signale als freiwillige Verkäufe am offenen Markt aussendet. Die Transaktion entspricht etwa 0,3 % von Badawis Beständen nach der Transaktion und einem unbedeutenden Anteil an den insgesamt ausstehenden SGHT-Aktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Badawi David

(Last) (First) (Middle)
C/O SIGHT SCIENCES, INC.
4040 CAMPBELL AVE., SUITE 100

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technology Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/03/2025 S 5,679(1) D $4.174 1,831,025 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.
/s/ Jeremy Hayden, Attorney-in-Fact for David Badawi 07/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Sight Sciences (SGHT) shares did CTO David Badawi sell?

Badawi sold 5,679 common shares on 03 Jul 2025.

What price did the SGHT shares sell for?

The reported average sale price was $4.174 per share.

Why were the SGHT shares sold?

The sale was to cover tax liabilities arising from RSU vesting, per the Form 4 footnote.

How many SGHT shares does Badawi own after the sale?

He directly owns 1,831,025 shares following the transaction.

Is this insider sale considered material to Sight Sciences?

Given the small size (~0.3 % of his holdings), it is not considered material to SGHT’s overall valuation.

Was this sale under a Rule 10b5-1 plan?

The filing does not indicate a Rule 10b5-1 plan checkbox as marked; only an automatic tax-withholding sale is disclosed.
Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Latest SEC Filings

SGHT Stock Data

193.24M
41.39M
20.61%
50.32%
2.09%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
MENLO PARK